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http://dx.doi.org/10.1016/j.bbmt.2013.05.007It has been with great consternation that I have been
following what appears to be an increasing wave of attacks
on the validity of using mouse models, with even the lay
press highlighting recent studies and questioning the
relevance of funding research involving mouse models
[1]. Unfortunately, as is all too often the case, superﬁcial
assessments often can be very deleterious and misused in
shaping overall opinions, not only in the lay press, but also
within the scientiﬁc community. This is particularly apparent
to those of us who serve on study sections and with the
current limitations in funding, we see how subjective
grading on “impact” and “signiﬁcance” can be adversely
affected rather easily. It has reached a point where some
reviews and editorials have been promoting “pro” and “con”
camps and literally keeping score of “hits” and “misses” with
regard to mouse models’ track record for clinical drug record
success; as if a ﬁnal tally would provide ﬁnal validation of
either viewpoint when in reality, many have already made
up their minds well in advance.
For biomedical researchers well-versed in using the
mouse as a preclinical model, the issue is not whether there
are limitations in attempting to directly extrapolate the
ﬁndings clinically. Clearly, there are. Rather, the issue is
understanding the model’s limitations to be able to glean the
useful information from it and not overinterpret the results.
That there exist signiﬁcant interspecies differences between
mouse and man is not debatable. Furthermore, some of the
preclinical models used to mimic human disease states can
appear very contrived in an effort to maintain sufﬁcient
control of the numerous variables, sometimes taken to
extreme lengths to obtain clear data to a point where the
clinical relevance is indeed questionable. This is at times in
the forefront when studying issues in cancer immunology
and hematopoietic stem cell transplantation (HSCT). Finally,
the very manner in which mice are inbred and housed in
speciﬁc pathogen-free environments result in more distance
from the human condition. However, many of these issues
can be resolved, at least partially, not by discarding the
model entirely, but rather by improving on it and, impor-
tantly, recognizing the mouse model as a tool that serves as
a screen for further development.
It is evident that use of the mouse model has resulted in
invaluable and signiﬁcant advances crossing manyowdisciplines in biomedical research, resulting in successful
clinical extrapolation. This is particularly germane in the
ﬁelds of immunology and hematology. Perhaps immunology
more than any other ﬁeld owes its depth of knowledge to
mouse studies. Fundamental concepts, including immune
tolerance, thymic education, T cell subsets (including regu-
latory T cells), natural killer cell biology (the discovery of
natural killer cell activity can be traced through classic
studies in mice with regard to bone marrow cell rejection in
the 1960s), dendritic cells, Toll-like receptors, fundamental
concepts in transplantation immunology, and immune cell
signaling, were pioneered and developed in the mouse. The
understanding of these processes at cellular and molecular
levels has facilitated preclinical development and subse-
quent successful therapeutic interventions in HSCT with
regard to conditioning, immune suppression, and anti-
inﬂammatory therapy [2]. The complex nature of cancer
immunology and therapeutic intervention calls for use of the
mouse model as a pivotal step, given recent data indicating
that the inherent complexity of the tumor microenviron-
ment alone is much greater than previously envisioned [3].
Detractors of the validity of mouse modeling using only
mice point to its deﬁciencies, but the alternatives are even
more fraught with hurdles and contrivances that limit
extrapolation, particularly regarding the study of immune
phenomena occurring in allogeneic HSCT and cancer. Large
animal models are extremely costly, often precluding
a sufﬁcient sample size, have a lack of reagents to allow for
adequate mechanistic dissection, and can have extremely
wide variability associated with outcomes. Xenograft models
in which human immune cells are placed into immunodeﬁ-
cient mice, although having the advantage of assessing
human cells in vivo, are even more artifact-ridden owing to
the extensive interspecies differences, which can result in
unnatural compensation of some factors and loss of others.
The only other recourse is in vitro modeling, which clearly
fails to mirror the complex physiological interactions of
multicellular organ systems as well as long-term effects.
What is the answer? Clinical trials cannot be performed
simply through ideas alone. It is true that many drugs that
show preclinical promise using mouse models fail in the
clinic; however, it is also true that numerous therapeutic
agents that show initial clinical promise fail under the
scrutiny of larger trials. The mouse model is a tool, nothing
more. It is important to avoid overinterpreting the data
gleaned from this model and to acknowledge its deﬁciencies.
Conversely, it is also critical to not overinterpret negative
data with regard to a linkage between mouse and man. A
model can be geared to show similarities or highlighted toTransplantation.
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tiﬁcation capabilities and speciﬁc gene signatures, might not
be the optimal readout when determining the precise rele-
vance of various disease models [1]. This debate has pro-
gressed to the point at which subjective interpretation has
resulted in the capability to spin the same data to support
both viewpoints.
It is clear that there are no easy solutions and that no
model can completely replicate the human scenario. Work
on reﬁning and improving the mouse model continue. The
use of aged mice (given that the average age of an individual
diagnosed with cancer is well over 50 years old), sponta-
neous or slower-growing tumor models (more reﬂective of
human cancer progression), mice under nonspeciﬁc
pathogen-free conditions, mice of both sexes, and multiple
strains are making the mouse model more reﬂective of
human scenarios [4]. Encouragingly, there has been signiﬁ-
cant improvement in the HSCT ﬁeld, in that many of these
variables are now being taken into consideration. The bar is
being raised. Concepts such as using several strain combi-
nations for graft-versus-host disease studies, using dose
responses (rather than simply the dose that provides the best
data), and not relying solely on gene knockoutmice for target
validation are now being incorporated to a greater extent,
resulting in more accurate assessment for possible extrapo-
lation. Therein lies another problem. Altering these param-
eters is more expensive to implement, takes more time and
can lack novelty. Funding agencies need to encourage
development and incorporation of these variables. Unfortu-
nately, the use of youngmicewith transplantable tumor lines
as a quick preclinical screen is an endpoint for most cancer
studies; resulting in publication but stopping there. It is very
difﬁcult to then proceed to the use of more expensive longer-term or more realistic models, given that the extent of
information obtained is often viewed as incremental. Thus,
the mouse model has enormous potential and needs to be
optimized, not discarded. Rather than jump on the band-
wagon of naysayers questioning the validity of funding
mouse studies, our community needs to be even more vocal
in demanding funding for the development of more realistic
applications and further optimization of the model. The
other options for developing clinical hypotheses and eluci-
dating physiological processes in the absence of mouse
modeling clearly are not superior, and simply remaining
passive in this debate, thinking that common sense will
make it dissipate with the passage of time, may result in
a huge step backward.
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